GlassScriptPhysician profile
Katie Staphos
NPI 1760488001
$5,061.16
in general payments reported to CMS, 2019-2025
23 companies · $832 in 2025
The $832 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $668 · 2022: $387 · 2023: $1,716 · 2024: $1,459 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,580 · Travel and Lodging: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,579.55 |
| Travel and Lodging | $426.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,513.37 | 2021-2025 | Watchman Access System, Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $746.59 | 2021-2025 | Farxiga |
| Abiomed | $443.96 | 2024-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $316.05 | 2022-2025 | |
| Abbott Laboratories | $314.89 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Merck Sharp & Dohme LLC | $226.07 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $208.46 | 2022-2025 | Eliquis, Camzyos |
| Pfizer INC. | $204.67 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $165.01 | 2021-2023 | Lifevest |
| Novo Nordisk INC | $163.77 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $132.48 | 2021-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2023 | Jardiance |
| Shockwave Medical, INC | $90.52 | 2025 | |
| Janssen Pharmaceuticals, INC | $89.03 | 2021-2024 | Xarelto |
| Chiesi USA, INC. | $52.09 | 2024-2025 | Cleviprex, Kengreal |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $49.82 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $43.71 | 2024 | |
| Alnylam Pharmaceuticals INC. | $42.64 | 2021-2025 | Amvuttra |
| Esperion Therapeutics, INC. | $40.07 | 2024-2025 | Nexletol |
| Scpharmaceuticals INC. | $34.83 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.21 | 2025 | |
| Celgene Corporation | $20.36 | 2021 | |
| Becton, Dickinson and Company | $13.56 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Staphos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.